Advanced Endometrial Cancer in the Immunotherapy Age - Baseline Assessment

Launch Date:
March 02, 2023

Primary Audience:

This activity is intended to meet the educational needs of healthcare professionals involved in the care of patients with endometrial cancer.

The following questions are designed to assess your knowledge and practice of patients with endometrial cancer.

Christina Chu, MD

Interim Chief, Division of Gynecologic Oncology
Professor, Department of Surgical Oncology
Director, Gynecologic Oncology Fellowship Program
NCCN, Cervical/Uterine Cancers Panel Member
Fox Chase Cancer Center
Philadelphia, PA

Dr. Christina Chu is a Professor of Gynecologic Oncology at the Fox Chase Cancer Center in Philadelphia.  Her practice focuses on the multimodality therapy of gynecologic malignancies.  She has served as Program Director for the Gynecologic Oncology Fellowship Program and her research interests include clinical trials for the treatment of gynecologic cancers, as well as survivorship issues for women with endometrial cancer.

Stephanie Wethington, MD, MSc

Director, The Susan L. Burgert MD Gynecologic Oncology Survivorship Program
Assistant Professor of Gynecology and Obstetrics
Johns Hopkins University School of Medicine
Baltimore, MD

Stephanie Wethington, M.D., M.Sc., is a board-certified gynecologic oncologist who treats patients with a range of gynecologic cancers including uterine, cervical, vulvar, vaginal and ovarian cancer, as well as gestational trophoblastic disease. She is an assistant professor in the Kelly Gynecologic Oncology Service of the Johns Hopkins Department of Gynecology and Obstetrics.

Dr. Wethington provides comprehensive surgical and medical cancer treatment, specializing in minimally invasive surgery and fertility-sparing methods. She works closely with her patients to create tailored treatment plans using the most advanced options and with access to groundbreaking clinical trials, guiding them through the full continuum of their cancer care.

Dr. Wethington completed a fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center. Before that, she completed her medical degree and residency in obstetrics and gynecology at Columbia University. She also earned a master’s degree at the University of Oxford and her undergraduate degree at Brandeis University. Prior to joining Johns Hopkins, Dr. Wethington was a gynecologic oncologist in the Washington, D.C., metropolitan area.

With a particular interest in cancer survivorship, she leads the Susan L. Burgert MD Gynecologic Oncology Survivorship Program. This program addresses the unmet needs of gynecologic oncology patients and their caregivers, family members and friends as they navigate through the cancer care journey and beyond, helping them to not only manage the process but to thrive. One of the only standalone gynecologic oncology survivorship programs in the country, it offers a point of connection, supportive programming, education and awareness. The team uses its experience and dedication to help survivors of women’s cancer live their lives to the fullest.

Dr. Wethington has been recognized for her clinical care approach and leadership with awards including the Johns Hopkins Emerging Women’s Leadership award. Other honors include being named among the best doctors in the Washington, D.C., area by Washingtonian magazine. Her research focuses on critical elements in the supportive care of gynecologic oncology patients, including patient-reported outcomes, disparities and perioperative care. She has received National Institutes of Health funding for her research through both ovarian and cervical care Specialized Programs of Research Excellence (SPORE) examining novel use of poly-ADP ribose polymerase (PARP) inhibitors and geographic care disparities, respectively. An expert in her field, Dr. Wethington and has been featured in numerous press releases and interviewed by media outlets including CBSand Parents magazine.

Professional organizations of which she is a member include the Society of Gynecologic Oncology, the American College of Obstetricians and Gynecologists, and the American Society of Clinical Oncology.

Apply knowledge of the underlying pathophysiology of endometrial cancer, as it relates to: (1) dysregulation of signaling and immune checkpoint pathways, biomarker testing and (2) molecular classification of high-risk EC (e.g., p53abnl, POLE, dMMR).
Incorporate recently published clinical data into management strategies for advanced/recurrent endometrial cancer.
Employ evidence- and guideline-based recommendations for the recognition and management of advanced and recurrent endometrial cancer using robust clinical cases.
Use best practices to identify and appropriately manage endometrial cancer irAEs.